SLDB Solid Biosciences Inc

Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
EN
01/10/2020

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...

June 3, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Participate at the Jefferies Global Healthcare Co...

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET. A live webcast of the fireside chat will be available on the Events page of the I...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports First Quarter 2025 Financial Results and Pro...

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the ...

May 15, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Participate at The Citizens Life Sciences Confere...

Solid Biosciences to Participate at The Citizens Life Sciences Conference CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by . The webca...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch